Ex Vivo Tumor Assay Using Artificial Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ex vivo assays for cancer drugs often fail to accurately predict clinical effectiveness due to the absence of the tumor microenvironment, leading to inconsistencies between test results and actual patient responses, particularly in hematological malignancies like CLL and MM.
Innovation Solution
The method involves creating an artificial environment (AE) by recombining discarded fractions from density gradient isolation of tumor samples, specifically the plasma and erythrocyte layers, to mimic the in vivo microenvironment, enhancing the viability and proliferation of primary tumor cells in ex vivo assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If ex vivo assays are performed without microenvironment components, then assay simplicity and ease of operation are improved, but the predictive accuracy and reliability of drug testing deteriorate
Solution Approach 1:
The patent introduces an artificial microenvironment composed of soluble factors (cytokines, chemokines, growth factors) and extracellular matrix components as an intermediary system. This mediator recreates the essential signaling and structural elements of the tumor microenvironment without requiring living non-tumor cells, thereby maintaining assay simplicity while significantly improving predictive accuracy of drug responses
Solution Approach 2:
The invention creates a simplified copy of the tumor microenvironment by isolating and reproducing its key functional components (soluble factors and ECM) in an artificial system. This copying approach captures the essential microenvironmental influences on tumor cells without the complexity of maintaining complete cellular ecosystems, resolving the contradiction between operational ease and predictive reliability
2Reliability
If the tumor microenvironment is fully reconstructed with all cellular components, then the predictive accuracy of drug testing is improved, but the device complexity and assay difficulty increase
Solution Approach 1:
The patent extracts only the essential functional components of the tumor microenvironment (soluble factors and ECM) while leaving behind the complex cellular elements (non-tumor cells). This selective extraction maintains the critical predictive functions of the microenvironment while dramatically reducing assay complexity, as the artificial environment can be prepared as a standardized composition without requiring maintenance of living cell populations
Solution Approach 2:
The invention applies local quality by providing microenvironmental support only where and when needed - through soluble factors and ECM components in the culture medium - rather than attempting to recreate the entire microenvironmental ecosystem. This localized approach delivers the necessary predictive accuracy for drug testing while avoiding the unnecessary complexity of full microenvironmental reconstruction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the accuracy of drug testing by mimicking the in vivo microenvironment, enhancing the sensitivity and predictive power of ex vivo assays for anti-tumor drug responses, allowing for more effective evaluation of drug efficacy and potential benefits for patients.
Implementation Method 1
discarded fractions from density gradient isolation of tumor samples, specifically the plasma and erythrocyte layers
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The invention presented here relates to a method for producing an artificial environment of primary cell populations, particularly an artificial tumor environment of primary tumor cell populations and its use in an ex vivo method to test the cellular responsiveness of primary tumor cell populations to a drug or drugs. The method of the invention comprises incubation of the primary tumor cells with the artificial tumor environment and the drug or drugs and analyze the response of the primary tumor cell populations. The incubation of the primary tumor cells with the artificial tumor environment, enhances the viability of said tumor cells and/or induces greater levels of tumor cell proliferation and, consequently, increases the sensitivity and accuracy of the test with regard to the drug/s assayed.